NCT06167681View on ClinicalTrials.gov

The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 17, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

July 31, 2029

Conditions
Parkinson Disease
Interventions
BIOLOGICAL

Human Dopaminergic Progenitor Cells

Single injection of Human Dopaminergic Progenitor Cells into the putamen/striatum region of brain.

Trial Locations (2)

100730

RECRUITING

Beijing Hospital, Beijing

430071

NOT_YET_RECRUITING

Zhongnan Hospital of Wuhan University, Wuhan

All Listed Sponsors
lead

iRegene Therapeutics Co., Ltd.

INDUSTRY